CQS Cayman’s Teva Pharmaceuticals TEVA Stock Holding History

CQS Cayman’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,800	Closed	-$497K	–	133
2016 Q3	$497K	Sell	10,800 -154,589	-93%	-$8.07M	0.04%	118
2016 Q2	$8.31M	Sell	165,389 -47,047	-22%	-$2.5M	0.73%	36
2016 Q1	$11.4M	Buy	212,436 +175,558	+476%	+$10.3M	1.14%	23
2015 Q4	$2.42M	Buy	+36,878	New	+$2.28M	0.17%	87
2015 Q3	–	Sell	-50,000	Closed	-$2.96M	–	193
2015 Q2	$2.96M	Sell	50,000 -30,400	-38%	-$1.88M	0.18%	96
2015 Q1	$5.01M	Buy	+80,400	New	+$4.67M	0.24%	80

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

CQS Cayman's TEVA Position: Q4 2016 in Review

CQS Cayman sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 10,800 shares — an estimated $497K sold.

CQS Cayman first reported a position in TEVA in Q1 2015 and held it in 6 quarters. The position peaked at $11.4M in Q1 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

CQS Cayman reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
CQS Cayman sold 10,800 Teva Pharmaceuticals shares in Q4 2016, an estimated $497K.
CQS Cayman first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 6 quarters.
CQS Cayman's Teva Pharmaceuticals position peaked at $11.4M in Q1 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on CQS Cayman's 13F filing for Q4 2016, filed 14 Feb 2017.